In a May 25 letter to the Food and Drug Administration (FDA), Senate Finance Committee leadership called attention to letters submitted to the agency by 2 medical groups and a Duke University professor who had financial ties to the drug maker Sanofi-Aventis. The letters, sent in 2008, supported the company's citizen petition requesting a delay in approval of generic versions of its blood-thinner Lovenox, which had annual sales of almost $3 billion (http://1.usa.gov/kitKjQ). The FDA approved a generic version in 2010.
Mitka M. Lobbying Efforts Questioned. JAMA. 2011;306(2):145. doi:10.1001/jama.2011.923